Selling, General, and Administrative Costs: Corcept Therapeutics Incorporated vs Taro Pharmaceutical Industries Ltd.

Corcept vs. Taro: A Decade of SG&A Expense Trends

__timestampCorcept Therapeutics IncorporatedTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 20143491600091733000
Thursday, January 1, 20153694900087644000
Friday, January 1, 20164524000092365000
Sunday, January 1, 20176241600085656000
Monday, January 1, 20188128900088196000
Tuesday, January 1, 201910035900089971000
Wednesday, January 1, 202010532600093413000
Friday, January 1, 202112235600091355000
Saturday, January 1, 2022152848000113676000
Sunday, January 1, 2023184259000198366000
Monday, January 1, 2024218935000
Loading chart...

Unleashing insights

A Comparative Analysis of SG&A Expenses: Corcept vs. Taro

In the competitive landscape of pharmaceuticals, managing operational costs is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Corcept Therapeutics Incorporated and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Corcept's SG&A expenses surged by over 400%, reflecting its aggressive growth strategy. In contrast, Taro's expenses grew by approximately 116%, indicating a more stable cost management approach. Notably, in 2023, Taro's expenses peaked at nearly 2.2 times that of Corcept's, highlighting its expansive operational scale. However, data for Corcept in 2024 is missing, leaving room for speculation on its future financial trajectory. This comparison underscores the diverse strategies these companies employ in navigating the pharmaceutical industry's financial challenges.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025